 |
|
Use of Flurbiprofen to Inhibit Corneal Neovascularization
Charles A. Cooper, MD;
Michael V. W. Bergamini, PhD;
Irving H. Leopold, MD, DSc
Arch Ophthalmol. 1980;98(6):1102-1105.
Abstract
• Following the suggestion that prostaglandins are involved in corneal neovascularization, two inhibitors of prostaglandin formation, prednisolone acetate and flurbiprofen sodium, have been evaluated in two experimental models of corneal neovascularization. The fatty acid cyclooxygenase inhibitor, flurbiprofen, at concentrations of 0.01% and 0.1%, significantly decreased the rate of vessel growth compared with vehicle controls in both silver nitrate cauterization and anterior chamber alloxan models of corneal neovascularization. Prednisolone, at a concentration of 1%, was used as a positive control. It did inhibit neovascularization in the latter model, but was ineffective in the former. It is concluded that 0.1% flurbiprofen is equipotent to 1% prednisolone as an inhibitor of corneal neovascularization. The mechanism is unknown but is likely to be via inhibition of prostaglandin formation and/or inhibition of leukocytic infiltration.
Author Affiliations
From the Department of Ophthalmology, University of California, Irvine.
Footnotes
Accepted for publication Sept 24, 1979.
Reprint requests to Department of Ophthalmology, University of California, Irvine, CA 92717 (Dr Leopold).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Histopathology of Corneal Neovascularization: Inhibitor Effects
Robin et al.
Arch Ophthalmol 1985;103:284-287.
ABSTRACT
Disposition of Topical Flurbiprofen in Normal and Aphakic Rabbit Eyes
Anderson et al.
Arch Ophthalmol 1982;100:642-645.
ABSTRACT
Ocular Neovascularization With Retinal Vascular Occlusion: I. Association With Experimental Retinal Vein Occlusion
Virdi and Hayreh
Arch Ophthalmol 1982;100:331-341.
ABSTRACT
|
